X4 PHARMACEUTICALS, INC Stock Issued During Period, Shares, Employee Stock Purchase Plans
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- X4 PHARMACEUTICALS, INC stock issued during period, shares, employee stock purchase plans for fiscal 2023 was 257.96K shares, a 25.90% increase from fiscal 2022.
- X4 PHARMACEUTICALS, INC stock issued during period, shares, employee stock purchase plans for fiscal 2022 was 204.90K shares, a 347.23% increase from fiscal 2021.
- X4 PHARMACEUTICALS, INC stock issued during period, shares, employee stock purchase plans for fiscal 2021 was 45.82K shares, a 71.96% increase from fiscal 2020.
- X4 PHARMACEUTICALS, INC stock issued during period, shares, employee stock purchase plans for fiscal 2020 was 26.64K shares.
| Period end | Stock Issued During Period, Shares, Employee Stock Purchase Plans 3 month | Stock Issued During Period, Shares, Employee Stock Purchase Plans 12 month |
|---|---|---|
| 2023-12-31 | 257.96K shares 10-K · filed 2025-03-26 | |
| 2022-12-31 | 204.90K shares 10-K · filed 2025-03-26 | |
| 2021-12-31 | 45.82K shares 10-K · filed 2024-03-21 | |
| 2020-12-31 | 26.64K shares 10-K · filed 2023-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |